NYSE · Healthcare · Drug Manufacturers—General
Merck & Co., Inc. (MRK)
As of Sep 25, 4:03 PM ET, Merck & Co. (MRK) last traded at $148.78, up 0.54% on the day. Its TickerHum research score is 51/100 (average). It reported revenue of $66.57B for the twelve months ending 2026-06-30, up 4.6% year over year.
Ratings
- Valuation: 47/100 — Strongest input: price / sales (ttm) 5.5x. Weakest: price / earnings (ttm) 119.0x.
- Growth: 19/100 — Strongest input: revenue growth (ttm, yoy) +4.6 %. Weakest: diluted eps growth (ttm, yoy) -80.7 %.
- Profitability: 37/100 — Strongest input: net margin 4.8 %. Weakest: return on equity 7.6 %.
- Financial health: 31/100 — Strongest input: long-term debt / equity 1.22. Weakest: cash / long-term debt 0.13.
- Momentum: 90/100 — Strongest input: 1-year return +89.4 %. Weakest: 6-month return +25.1 %.
- Attention: 57/100 — Strongest input: headlines in the last 7 days 35. Weakest: volume vs 3-month average 0.8x.
- Risk: 82/100 — Strongest input: max drawdown (1y) -11.9 %. Weakest: annualised volatility (1y) 30.0 %.
- Data confidence: 89/100 — Strongest input: latest financial period age (days) 59 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $66.57B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 4.6% | TTM ending 2026-06-30 · 10-Q |
| Net income | $3.17B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | $1.25 | TTM ending 2026-06-30 · 10-Q |
| Net margin | 4.8% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | $16.06B | TTM ending 2026-06-30 · 10-Q |
| Cash | $6.85B | as of 2026-06-30 · 10-Q |
| Long-term debt | $51.08B | as of 2026-06-30 · 10-Q |
| Debt / equity | 1.22 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000310158).
Compare Merck & Co. with its closest competitors
- Merck & Co. vs Pfizer (MRK vs PFE) — Same industry (Drug Manufacturers—General); market cap 0.45x; shares: oncology, vaccines
- Merck & Co. vs AbbVie (MRK vs ABBV) — Same industry (Drug Manufacturers—General); market cap 1.3x; shares: oncology
- Merck & Co. vs Amgen (MRK vs AMGN) — Same industry (Drug Manufacturers—General); market cap 0.61x; shares: oncology
- Merck & Co. vs Gilead Sciences (MRK vs GILD) — Same industry (Drug Manufacturers—General); market cap 0.51x; shares: oncology
- Merck & Co. vs Bristol-Myers Squibb (MRK vs BMY) — Same industry (Drug Manufacturers—General); market cap 0.35x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.